Image of Anti-Angiogenics: Their Value in Lung Cancer Therapy

LITERATURE

Anti-Angiogenics: Their Value in Lung Cancer Therapy


Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)- A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy


Availability

REQJ4612-2Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Oncol Res Treat 2018;41:172–180
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous